Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Other Operating Expense for the
three
months ended in Mar. 2026 was $13 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $756 Mil.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's quarterly Other Operating Expense
increased
from Sep. 2025 ($-379 Mil) to Dec. 2025 ($738 Mil) but then
declined
from Dec. 2025 ($738 Mil) to Mar. 2026 ($13 Mil).
Guangzhou Baiyunshan Pharmaceutical Holdings Co's annual Other Operating Expense
declined
from Dec. 2023 ($724 Mil) to Dec. 2024 ($684 Mil) but then
increased
from Dec. 2024 ($684 Mil) to Dec. 2025 ($748 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Other Operating Expense Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $756 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of $756 Mil mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (GZPHF) has a Other Operating Expense of $756 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Other Operating Expense too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Other Operating Expense is $756 Mil. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Other Operating Expense compare to MCK and COR?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Other Operating Expense of $756 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Distribution company?
A good Other Operating Expense depends on the Medical Distribution industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Other Operating Expense is $756 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (GZPHF) has a current Other Operating Expense of $756 Mil. The stock's GF Value™ is $3.20, compared to a current price of $2.34 — trading 26.9% below its estimated fair value. The current Other Operating Expense is $756 Mil. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (GZPHF), the current Other Operating Expense is $756 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (GZPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of $2.34 is trading 26.9% below its estimated GF Value™ of $3.20.
Key valuation signals for GZPHF:
Other Operating Expense: $756 Mil
GF Value™: $3.20 vs. price of $2.34 (26.9% below fair value)
No single metric tells the full story. See the GZPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
68GF Score
Get the complete analysis for GZPHF
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GZPHF has been successfully added to your 
